v3.26.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2025
Accounting Policies [Abstract]  
Schedule of Financial Instruments Measured at Fair Value on Recurring Basis

The following tables set forth the fair value of the Company’s consolidated financial instruments that were measured at fair value on a recurring basis as of December 31, 2025 and December 31, 2024:

 

   Level 1   Level 2   Level 3   Total 
       December 31, 2025     
   Level 1   Level 2   Level 3   Total 
Cash and cash equivalents    2,917,721       -     -    2,917,721 
                     
Total fair value   2,917,721    -    -    2,917,721 
Schedule of Property and Equipment Estimated Useful Lives

 

Laboratory equipment   5 years
Furniture and fixtures   7 years
Leasehold improvements   Lesser of the lease duration or the life of the improvements
Schedule of Property and Equipment

Property and equipment consist of the following as of December 31, 2025 and 2024, respectively:

 

   December 31, 2025   December 31, 2024 
         
Laboratory equipment  $ 1,397,939   $ 1,277,647 
Furniture and fixtures   54,338    54,338 
Leasehold improvements   328,786    279,161 
Total property and equipment   1,781,063    1,611,146 
Less: Accumulated depreciation   (1,016,662)   (728,701)
Property and equipment, net  $ 764,401   $ 882,445 
Schedule of Grants Receivable Activity

Summary of grants receivable activity for the years ended December 31, 2025 and 2024, is presented below:

 

   December 31, 2025   December 31, 2024 
Balance at beginning of period  $ 737,282   $ 882,319 
Grant costs expensed   1,569,165    2,235,163 
Grants for equipment purchased   19,699    43,615 
Grant fees   18,830    54,944 
Grant funds received   (1,827,617)   (2,478,759)
Balance at end of period  $517,359   $737,282